Precision cancer medicine (PCM) to support the treatment of solid tumors requires minimally invasive diagnostics. Here, we describe the development of fine-needle aspiration biopsy-based (FNA) molecular cytology which will be increasingly important in diagnostics and adaptive treatment. We provide support for FNA-based molecular cytology having a significant potential to replace core needle biopsy (CNB) as a patient-friendly potent technique for tumor sampling for various tumor types. This is not only because CNB is a more traumatic procedure and may be associated with more complications compared to FNA-based sampling, but also due to the recently developed molecular methods used with FNA. Recent studies show that image-guided FNA in combination with ultrasensitive molecular methods also offers opportunities for characterization of the tumor microenvironment which can aid therapeutic decisions. Here we provide arguments for an increased implementation of molecular FNA-based sampling as a patient-friendly diagnostic method, which may, due to its repeatability, facilitate regular sampling that is needed during different treatment lines, to provide tumor information, supporting treatment decisions, shortening lead times in healthcare, and benefit healthcare economics.

中文翻译：

---

基于微创活检的诊断支持精准癌症医学

支持实体瘤治疗的精准癌症医学 (PCM) 需要微创诊断。在这里，我们描述了基于细针抽吸活检（FNA）的分子细胞学的发展，这在诊断和适应性治疗中将变得越来越重要。我们为基于 FNA 的分子细胞学提供支持，该技术具有取代核心针活检 (CNB) 的巨大潜力，成为一种对患者友好的有效技术，用于各种肿瘤类型的肿瘤采样。这不仅是因为 CNB 是一种创伤性更大的手术，与基于 FNA 的取样相比可能会导致更多并发症，而且还因为最近开发的用于 FNA 的分子方法。最近的研究表明，图像引导 FNA 与超灵敏分子方法相结合也为表征肿瘤微环境提供了机会，从而有助于治疗决策。在这里，我们提供了更多实施基于分子 FNA 的采样作为一种对患者友好的诊断方法的论据，由于其可重复性，该方法可以促进不同治疗线期间所需的定期采样，以提供肿瘤信息，支持治疗决策，缩短医疗保健的交付时间，并有利于医疗保健经济。